Optimi Health Corp.

CSE: OPTI

Company Logo

Company Overview

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. 

To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations.

Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.

Financial Highlights

$37,982

Revenue (ttm)

-$43,326

Gross Profit (ttm)

-$0.14

Diluted EPS (ttm)

Management Team

Mr. John James Wilson
Co-Founder & Non-Exec. Chairman

Mr. William J. Ciprick
Chief Exec. Officer

Mr. Bryan Edward Safarik
Co-Founder, COO & Director

Mr. Jacob Safarik
Co-Founder, CFO & Director

Mr. Dane Stevens
Co-Founder, Chief Marketing Officer & Director

Mr. Justin D. Kirkland
Chief Science Officer and Member of PIR Medical & Clinical Advisory Board

Laura Chow
Director of Products & Sales

Mr. Todd Henderson
Head of Cultivation

Ms. Leah Hodges
Corp. Sec.

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
()

Insider Ownership
15%